Adjunctive therapies for proliferative vitreoretinopathy

International Ophthalmology Clinics

Volumn 44, Issue 3, 2004, Pages 1-10

  Sun, Jennifer K ^b   Arroyo, Jorge G ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' BENZOYLOXYCINNAMALDEHYDE; BLEOMYCIN SULFATE; CINNAMALDEHYDE DERIVATIVE; CISPLATIN; COLCHICINE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; HEPARIN; HERBIMYCIN A; HYPERICIN; LOW MOLECULAR WEIGHT HEPARIN; MATRIX METALLOPROTEINASE INHIBITOR; METHYLPREDNISOLONE; MITOMYCIN; PACLITAXEL; RETINOIC ACID; SURAMIN; TRANILAST; TRIAMCINOLONE; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; EYE SURGERY; HUMAN; MORBIDITY; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLOW RELEASE FORMULATION; SURGICAL PATIENT; TREATMENT OUTCOME; VITREORETINOPATHY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; VITREORETINOPATHY, PROLIFERATIVE;

EID: 3242709315     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404430-00003     Document Type: Review

References (43)

1. Barrada A, Peyman GA, Greenberg D, et al. Toxicity of antineoplastic drugs in vitrectomy infusion fluids. Ophthalmic Surg. 1983;10:845-847.
2. Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol. 1995;79:953-960.
3. Cowley M, Conway BP, Campochiaro PA, et al. Clinical risk factors for proliferative vitreoretinopathy. Arch Ophthalmol. 1989;107:1147-1151.
4. Girard P, Mimoun G, Karpouzas I, et al. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina. 1994;14:417-424.
5. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
6. Kon CH, Asaria RH, Occleston NL, et al. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol. 2000;84:506-511.
7. Mietz H, Heimann K. Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal diseases. Br J Ophthalmol. 1995;79:874-877.
8. Kim IK, Arroyo JG. Mechanisms in proliferative vitreoretinopathy. Ophthalmol Clin North Am. 2002;15:81-86.
9. Serag J. Shaken not stirred. Ophthalmology. 2001;108:1177-1178.
10. Campochiaro PA. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol. 1997;115:237-241.
11. Pastor JC, Rodriguez de la Rua E, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Ret Eye Res. 2002;21:127-144.
12. Machemer R. Proliferative vitreoretinopathy (PVR): a personal account of its pathogenesis and treatment. Invest Ophthalmol Vis Sci. 1988;29:1771-1783.
13. The Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121-125.
14. Lean JS, Stern WH, Irvine A, et al. The Silicone Study Group. Classification of proliferative vitreoretinopathy used in the Silicone Study. Ophthalmology. 1989;96:756-771.
15. Peyman GA, Schulman J. Proliferative vitreoretinopathy and chemotherapeutic agents. Surv Opthalmol. 1985;29:434-442.
16. Yang G-S, Khawly JA, Hainsworth DP, et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1998;116:69-77.
17. Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1992;33:3125-3130.
18. Borhani H, Peyman GA, Rahimy MH, et al. Suppresion of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU. Int Ophthalmol. 1995;19:43-49.
19. Hui YN, Liang HC, Cai YS, et al. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol. 1993;231:109-114.
20. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90:810-816.
21. Rubsamen PE, Cousins SW. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Retina. 1997;17:44-50.
22. Koerner F, Merz A, Gloor B, et al. Postoperative retinal fibrosis- a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol. 1982;219:268-271.
23. Hui YN, Hu D. Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease. Graefes Arch Clin Exp Ophthalmol. 1999;237:601-605.
24. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 200;84:1064-1066.
25. Lee JJ, Park JK, Kim Y-T, et al. Effect of 2′-benzoyl- oxycinnamaldehyde on RPE cells in vitro and in an experimental proliferative vitreoretinopathy model. Invest Ophthalmol Vis Sci. 2002;43:3117-3123.
26. Barrada A, Peyman GA, Case J, et al. Evaluation of intravitreal 5-fluorouracil, vincristine, VP 16, doxorubicin, and thiotepa in primate eyes. Ophthalmic Surg. 1984;9:767-769.
27. Kumar A, Nainiwal S, Choudhary I, et al. Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery. Clin Exp Ophthalmol. 2002;30:348-351.
28. Wiedemann P, Leinung C, Hilgers R-D, et al. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991;229:150-152.
29. Wiedemann P, Lemmen K, Schmiedl R, et al. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol. 1987;104:10-14.
30. Wiedemann P, Hilgers RD, Bauer P, et al. The Daunomycin Study Group. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy; results of a multicenter clinical trial. Am J Ophthalmol. 1998;126:550-559.
31. Esser P, Tervooren D, Heimann K, et al. Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1998;39:164-170.
32. Tahara Y, Sakamoto T, Oshima Y, et al. The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy. Curr Eye Res. 1999;19:323-329.
33. Imai K, Loewenstein A, Koroma B, et al. Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: toxicity and efficacy study. Graefes Arch Clin Exp Ophthalmol. 2000;238:440-447.
34. Ito S, Sakamoto T, Tahara Y, et al. The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1999;237:691-696.
35. van Bockxmeer FM, Martin CE, Thompson DE, et al. Taxol for the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1985;26:1140-1147.
36. Berman DH, Gombos GM. Proliferative vitreoretinopathy: does oral low-dose colchicines have an inhibitory effect? A controlled study in humans. Ophthalmic Surg. 1989;20:268-272.
37. Sakamoto T, Kimura H, Koda RP, et al. Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin. Ophthalmologica. 1995;209:212-216.
38. Ozerdem U, Mach-Hofacre B, Keefe K, et al. The effect of Prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res. 2001;33:20-23.
39. Wiedemann P. Drug treatment of ocular neovascularization and proliferation. Graefes Arch Clin Exp Ophthalmol. 1999;237:445-447.
40. Salah-Eldin M, Peyman GA, El-Aswad M, et al. Evaluation of toxicity and efficacy of a combination of antineoplastic agents in the prevention of PVR. Int Ophthalmol. 1994;18:53-60.
41. Berger AS, Cheng C-K, Pearson PA, et al. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1996;37:2318-2325.
42. Williams RG, Chang S, Comaratta MR, et al. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol. 1996;234:496-503.
43. Asaria RHY, Kon CH, Bunce C, et al. Khaw Pt, Aylward GW. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108:1179-1183.